CClinicalTrials.gg
CompletedNCT01478646Updated Nov 23, 2011

The Effect of Reflective Breathing Therapy Compared With Conventional Breathing Therapy in Patients With Chronic Obstructive Pulmonary Disease (COPD) III-IV

An interventional study of conventional breathing therapy and reflectory breathing therapy in Chronic Obstructive Pulmonary Disease, sponsored by Schön Klinik Berchtesgadener Land. Completed at 1 site in Germany. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-11-23.

Sponsored by Schön Klinik Berchtesgadener Land · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether different types of breathing therapies in patients with COPD III-IV decrease dyspnea and increase activity.

Read the detailed description

In the treatment of COPD-Patients different kinds of breathing therapy techniques are used, but many of them are not reassessed yet.

Dyspnea is one of the predominant symptoms of COPD patients and has negative impacts on the activity of the patients. Dyspnea during exertion leads to avoiding activity and results in a deconditioning of muscles and of the cardiovascular system.

Thus breathing therapy techniques seem to be useful, which may lead to a decrease of dyspnea and an increase of activity.

The purpose of this study is to determine whether reflective breathing therapy is more effective on decreasing dyspnea and increasing activity than conventional breathing therapy.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • breathing therapy
  • reflective breathing therapy
  • COPD
  • chronic obstructive pulmonary disease
03

In context

Lung Diseases

3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.

This study's enrollment of 24 is below the median of 72 across 2,118 interventional studies indexed under Lung Diseases.

Browse Lung Diseases studies →

Lead sponsor

Schön Klinik Berchtesgadener Land is the lead sponsor of 51 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • inpatient rehabilitation
  • COPD (Gold stage III and IV)

Exclusion criteria

Exclusion Criteria:

  • severe exacerbation in the last four weeks
  • acute infections
  • fever
  • neuritides
  • severe osteoporosis
  • skin disease
  • manic depression
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Conventional breathing therapy

    first: conventional breathing therapy, second: reflectory breathing therapy

    Other: conventional breathing therapy

  • Experimental
    Reflectory breathing therapy

    first: reflectory breathing therapy second: conventional breathing therapy

    Other: reflectory breathing therapy

Interventions

  • Otherconventional breathing therapy

    duration: 60 minutes.

  • Otherreflectory breathing therapy

    duration: 60 minutes.

06

What researchers measure

Primary outcomes

  1. Change in BORG-Scale

    Instrument for self-reported dyspnea; modified BORG-scale ranges from 1 (no dyspnea) to 10 (maximum dyspnea).

    Time frame: Change from pre (minute o) in BORG-scale at directly post intervention (minute 60)

Secondary outcomes

  1. Change in residual volume

    measured by a portable spirometry device

    Time frame: change from pre (minute 0) in residual volume at post (minute 60) intervention

07

Study locations

1 site
  • Schön Klinik Berchtesgadener Land
    Schönau, Bayern 83471, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 23, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01478646
Lead sponsor
Schön Klinik Berchtesgadener Land
Collaborators
University of Osnabrueck
Responsible party
Klaus Kenn (Head physician (department of pulmonology), Schön Klinik Berchtesgadener Land) — Principal investigator
First posted
Nov 23, 2011
Start date
Aug 2011
Primary completion
Nov 2011
Completion
Nov 2011
Last update
Nov 23, 2011

Study contacts

Klaus Kenn, Dr. med.
study chair · Schön Klinik Berchtesgadener Land
Stella Seeberg
principal investigator · University of Osnabrueck

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion